Plain-English translation of NCT06128551 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing two experimental medications called and in people with advanced cancers that have a specific genetic change (KRAS G12C mutation). You would receive the medication as a single drug or as a combination of both drugs, depending on which group you join. The study aims to find the safest and most effective dose and to see how well this treatment works against your cancer.
Current treatments for cancers with this genetic mutation have limited options, especially for patients who have already tried other therapies. This trial is designed to develop new treatment choices that may help patients whose cancers have stopped responding to existing drugs.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly for check-ups, blood tests, and imaging scans to monitor how the medication is working and check for side effects. Depending on which group you're assigned to, you would take one or both medications by mouth on a specific schedule. The study has two phases: an initial phase to find the right dose, followed by a larger phase to confirm safety and effectiveness, which may take several months or longer.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States